About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Lots of 500000 going through @ 0.0032 showing as sell but they must be buys.

Marcel
They are buys just checked Barclays 500000 to buy at .32

why do you think share price has dropped?

marcel1970 because the hype has

700202
The hype may have dropped but the volume hasnt a few months ago you would have been lucky to have seen a couple of trades for the whole day, happy to hold at these levels till we get more news. If you believe in ERX top up on the dips.

DRIVER I believe and am holding 5 mil and will top up , but get fed up with idiots putting old or unconnected news hype on the site
could be massive news for cancer sufferers, without the crap

what crap, its all relevant, its all about cancer.. so your statement is contradictive 700202

I think some of it PH is that its old and they have seen it all before !!

actually none of it is old, it comes straight from google news

ya plonker

Some is new yes, but some is old and some has jack sh*t to do with ERX + all links are at the top of this thread for all to read IF THEY WANT TO,AND WHAT plonker keeps saying news tomorrow a week ago !! :)))) IF Ramping was an Olympic sport you would get GOLD for sure !!

MGI PHARMA Recognized for Innovation & Growth
Nov 2 2006, 3:01 PM EST
BIOWIRE


MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced it has received two awards for product innovation and revenue growth. The Company was named a 2006 Minnesota Tekne Award winner in the Established Biotechnology category, and was ranked 212th on the Deloitte Technology Fast 500 list for North America.

"These two awards are testament to the hard work and dedication of our talented associates," stated Lonnie Moulder, President and CEO of MGI PHARMA. "I'd like to thank them for the critical roles they've played in enabling MGI PHARMA to bring to market innovative products for patients."

The Minnesota Tekne Awards honors companies, innovations and individuals that make a positive impact on Minnesota's technology-based economy. The Minnesota High Tech Association (MHTA) and Minnesota Technology, Inc. (MTI), in partnership with LifeScience Alley join together annually to celebrate and recognize those companies and individuals who have made superior contributions to the development, commercialization, and management of technology in the State of Minnesota.

The 2006 Deloitte Technology Fast 500 is a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. Rankings are based on percentage revenue growth over five years (2001-2005). MGI PHARMA's total revenue grew from $33 million to $279 million in this time frame.

To qualify for the Fast 500, entrants must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company's operating revenues or devotes a significant portion of revenues to research and development of technology. Base-year operating revenues must be at least $50,000 USD and current-year operating revenues must be at least $5 million USD. Companies must also be in business for five years and be headquartered within North America.

PH what does this have to do with ERX?

laurie squash , best thing is ignore his posts when news does come it will be on the site quick enough, holding 5 mil and happy

.

very relevant to us, note P53.. now I am starting help you.. thats not good

03 Nov 2006 Page 1
Revolutionary Eye Cancer Treatment
A new locally applied treatment for the eye cancer retinoblastoma has been developed by scientists at St. Jude Children's Research Hospital and demonstrated in a mouse model to cause a remarkable reduction in the size of the tumor, without causing the side effects common with standard chemotherapy. In addition the treatment also appears to be suitable for certain forms of breast, lung, prostate and colon cancer, and is simple enough for widespread use even in countries with limited resources.

A report on this work appears in the Nov. 2 issue of the journal Nature.

Retinoblastoma occurs in about 5,000 young children worldwide each year, arising from the immature retina, which is the part of the eye responsible for detecting light and color. The cancer is fatal if left untreated.

The new treatment holds promise for a simpler, more effective and less-toxic treatment for retinoblastoma that would eliminate the need for the current, complex therapy, according to senior author Michael Dyer, Ph.D., a Pew Scholar and associate member of the St. Jude Department of Developmental Neurobiology. The treatment is based on a discovery by Dyer's laboratory that overturned a widely held belief about the process of apoptosis (cell suicide) in retinoblastoma. Apoptosis is the way the body rids itself of abnormal cells that might become cancerous or cause other problems.

Until now, retinoblastoma experts thought that a mechanism called the p53 pathway triggered apoptosis in other types of cancer cells, but not in retinoblastoma. However, the St. Jude team proved not only that the p53 pathway was activated in early-stage retinoblastoma, but that excessive levels of a molecule called MDMX blocked it from triggering apoptosis in more advanced tumors. Based on this discovery, the St. Jude team used a molecule called nutlin-3 to block MDMX in retinoblastoma cells in test tube studies as well as in mouse models. The molecule was originally developed by Roche Pharmaceuticals (Nutley, N.J.) for a similar use against a related target called MDM2 in adult cancer

All those on ERX might want to take a look at ANTISOMA (ASM) as a side bet or the other way round.

ph good info thanks!

Market Report -- Short Stories (ALNY)advertisementRelated information E-mail this article Print-friendly versionStocks mentioned in this articleAlnylam Pharmaceuticals, Inc.(ALNY) Quote, Chart, News


All Briefing News
Alnylam Pharmaceuticals Bear Stearns downgrades Outperform to Peer Perform. Bear Stearns downgraded ALNY to Peer Perform from Outperform based on the significant appreciation of shares due to the acquisition of a competitor, and its implications for a take-out of ALNY. The firm believes the majority of major pharma/biotech firms are awaiting add'l validation of the RNAi platform, while Merck had been one of the most outspoken proponents. They do not view an acquisition of ALNY to be probable in the near-term, until positive efficacy data from its lead candidate for RSV infection, ALN-RSV01, suggests proof-of-concept; they expect the first read of efficacy from its experimental infection study around mid-2007.

driver, you should have mail ! : )